Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

6.410 +0.170 (+2.72%)
Streaming Delayed Price Updated: 10:57 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Joins Rare Disease Company Coalition
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Recap: Abeona Therapeutics Q1 Earnings
Via Benzinga
Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'
Via Benzinga
Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder
Via Benzinga
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy 
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports First Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
Three Small-Cap Biotech Stocks to Consider Now
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 
Via MarketBeat
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! 
Via InvestorPlace
PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. 
Via Benzinga
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces $35 Million Private Placement Financing
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via GlobeNewswire
How Is The Market Feeling About Abeona Therapeutics?
Abeona Therapeutics's (NASDAQ:ABEO) short percent of float has fallen 9.04% since its last report. The company recently reported that it has 177 thousand shares sold short, which is 3.02% of all... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Inventiva (NASDAQ:IVA) shares increased by 44.0% to $5.88 during Friday's regular session. The market value of their outstanding shares is at $247.6 million. 
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52. 
Via Benzinga
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday. 
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.